This session will review the cardiovascular risk factors in psoriasis and the impact of treatment. There will also be an overview on available biologics and how to best select the most appropriate biologic for each patient. There will be a lively debate on the use of oral agents as first line therapy. Managing nail psoriasis, genital psoriasis and psoriasis in women of child bearing potential will also be emphasized. There will also be discussion on management of psoriatic arthritis. The link between depression and psoriasis will be discussed. Is depression a comorbidity or a side effect?
This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
Dr. Elewski / Welcome and Introduction
Dr. Lebwohl / Overview of biologics for Psoriasis: How to select the best drug for your patient.
Dr. Gelfand / Cardiovascular risk in Psoriasis: Implications for your clinical practice
Dr. Gordon / Debate: Use oral medications before biologics
Dr. Langley / Debate: Biologics should be used first line
All faculty / Debate and Rebuttal: “Should we bypass oral medications and go direct to biologics in patients with moderate to severe psoriasis?”
Dr. Menter / Treatment of genital Psoriasis
Dr. Elewski / Treatment of nail Psoriasis
Dr. Wu / Depression and Psoriasis: Is this a comorbidity or side effect?
Dr. Blauvelt / Should TNF blockers still be first line in patients with PSA and PSO?
Dr. Kimball / Treatment of Psoriasis in pregnancy
All faculty / Panel